BioGend Therapeutics Co., Ltd.
BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd. (6733) - Total Liabilities
Latest total liabilities as of December 2025: NT$57.74 Million TWD
Based on the latest financial reports, BioGend Therapeutics Co., Ltd. (6733) has total liabilities worth NT$57.74 Million TWD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioGend Therapeutics Co., Ltd. - Total Liabilities Trend (2021–2025)
This chart illustrates how BioGend Therapeutics Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioGend Therapeutics Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of BioGend Therapeutics Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jr Global Reit
KO:348950
|
Korea | ₩1.59 Trillion |
|
KST BETEILIG N (KSW.SG)
STU:KSW
|
Germany | €3.01 Million |
|
DRAIG RESOURCES
BE:C7H
|
Germany | €375.11 Million |
|
Grounded People Apparel Inc.
PINK:GPAIF
|
USA | $885.34K |
|
Robert Walters
LSE:RWA
|
UK | GBX213.50 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down BioGend Therapeutics Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioGend Therapeutics Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioGend Therapeutics Co., Ltd. (2021–2025)
The table below shows the annual total liabilities of BioGend Therapeutics Co., Ltd. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$57.74 Million | -12.77% |
| 2024-12-31 | NT$66.19 Million | -29.37% |
| 2023-12-31 | NT$93.71 Million | +3.49% |
| 2022-12-31 | NT$90.56 Million | +12.61% |
| 2021-12-31 | NT$80.42 Million | -- |